SNTI revenueQ2 2026$17.0K
- QoQ
- +6.3%
SNTI revenue was $17.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and up 6.3% from the prior quarter. For the full fiscal 2025 it was $22.0K, compared with $0 in fiscal 2024.
Senti Biosciences Holdings Inc. (SNTI) financials
For fiscal 2025 (ended Dec 31, 2025), Senti Biosciences Holdings Inc. reported $22.0K of revenue and -$61.44M of net income.
- Revenue, FY2025
- $22.0K
- Net income, FY2025
- -$61.44M
- Net margin
- -279263.6%
- Free cash flow, FY2025
- -$43.64M
- EPS, diluted, FY2025
- -$2.73
- Cash
- $6.46M
- P/S
- 279.67
- Market cap
- $6.2M
FY2021FY2025
FY2021FY2025
FY2021FY2025
SNTI revenue and earnings growth
SNTI net incomeQ2 2026-$12.75M
SNTI net income was -$12.75M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$14.73M a year earlier. For the full fiscal 2025 it was -$61.44M, compared with -$52.79M in fiscal 2024.
SNTI EPSQ2 2026-$0.41
SNTI diluted EPS was -$0.41 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.56 a year earlier. For the full fiscal 2025 it was -$2.73.
SNTI free cash flowQ4 2025-$6.88M
SNTI free cash flow was -$6.88M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$13.52M a year earlier. For the full fiscal 2025 it was -$43.64M, compared with -$41.42M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $22.0K | $0 | $2.56M | $4.29M | $2.76M |
| Research and development | $37.59M | $34.36M | $32.15M | $28.14M | $21.96M |
| Selling, general and admin | $26.16M | $26.37M | $37.18M | $38.23M | $21.25M |
| Operating income | -$68.78M | -$61.04M | -$92.73M | -$62.08M | -$40.45M |
| Income tax | $0 | $0 | - | - | - |
| Net income | -$61.44M | -$52.79M | -$71.06M | -$58.21M | -$55.32M |
| EPS, basic | -$2.73 | -$12.03 | -$16.01 | -$22.30 | -$190.00 |
| EPS, diluted | -$2.73 | -$12.03 | -$16.01 | -$22.30 | -$190.00 |
| Diluted shares | 22.5M | 4.6M | 4.4M | 2.6M | 291,227.5 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $16.42M | $51.81M | $39.45M | $60.99M | $59.29M |
| Short-term investments | - | - | $0 | $40.94M | $0 |
| Receivables | - | - | - | $626.0K | $483.0K |
| Current assets | $23.27M | $58.96M | $71.20M | $102.58M | $60.19M |
| Total assets | $51.22M | $97.84M | $119.48M | $180.79M | $96.70M |
| Current liabilities | $13.97M | $13.15M | $12.67M | $18.05M | $14.54M |
| Total liabilities | $45.63M | $47.09M | $52.57M | $53.53M | $36.33M |
| Shareholders' equity | $5.59M | $25.65M | $66.91M | $127.26M | -$111.46M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$43.44M | -$41.40M | -$52.40M | -$34.90M | -$34.63M |
| Capital expenditures | $196.0K | $26.0K | $12.04M | $41.37M | $5.54M |
| Free cash flow | -$43.64M | -$41.42M | -$64.43M | -$76.27M | -$40.18M |
| Investing cash flow | -$184.0K | $34.0K | $30.08M | -$81.96M | -$5.54M |
| Financing cash flow | $11.76M | $53.73M | $779.0K | $118.55M | $68.44M |
| Stock-based compensation | $5.71M | $1.75M | $9.67M | $16.39M | $2.29M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | -40.2% | 55.2% | - |
| Operating margin | -312631.8% | - | -3620.7% | -1448.5% | -1464.9% |
| Net margin | -279263.6% | - | -2774.6% | -1358.1% | -2003.6% |
| Free cash flow margin | -198363.6% | - | -2515.9% | -1779.5% | -1455.2% |
| Return on equity | -1099.3% | -205.8% | -106.2% | -45.7% | - |
| Return on assets | -119.9% | -54.0% | -59.5% | -32.2% | -57.2% |
| Current ratio | 1.67 | 4.49 | 5.62 | 5.68 | 4.14 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0K | $16.0K | - | - | $0 | $0 | - | $1.66M | $1.59M | $1.46M | $0 | $338.0K |
| Research and development | $7.77M | $5.28M | $7.76M | $10.52M | $10.03M | $9.28M | $7.77M | $8.65M | $9.15M | $8.78M | $9.12M | $9.09M |
| Selling, general and admin | $6.74M | $6.23M | $5.85M | $6.43M | $6.77M | $7.12M | $8.08M | $6.56M | $4.21M | $7.52M | $9.30M | $9.43M |
| Operating income | -$14.49M | -$4.62M | -$18.64M | -$16.95M | -$16.80M | -$16.40M | -$16.17M | -$15.21M | -$13.36M | -$16.30M | -$18.70M | -$43.88M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 |
| Net income | -$12.75M | -$4.22M | -$14.47M | -$18.13M | -$14.73M | -$14.11M | -$610.0K | -$28.87M | -$11.20M | -$12.11M | -$71.06M | -$14.92M |
| EPS, basic | -$0.41 | -$0.14 | - | -$0.69 | -$0.56 | -$1.41 | -$0.62 | -$6.31 | -$2.45 | -$2.65 | -$4.23 | -$3.36 |
| EPS, diluted | -$0.41 | -$0.14 | - | -$0.69 | -$0.56 | -$1.41 | -$0.62 | -$6.31 | -$2.45 | -$2.65 | -$4.23 | -$3.36 |
| Diluted shares | 31.1M | 31.0M | - | 26.2M | 26.1M | 10.0M | - | 4.6M | 4.6M | 4.6M | - | 4.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.46M | $8.94M | $16.42M | $12.24M | $25.11M | $37.35M | $51.81M | $14.04M | $19.41M | $27.75M | $39.45M | $39.43M |
| Short-term investments | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Current assets | $13.01M | $14.79M | $23.27M | $18.16M | $32.52M | $45.21M | $58.96M | $17.38M | $44.34M | $55.67M | $71.20M | $79.01M |
| Total assets | $33.10M | $38.24M | $51.22M | $52.69M | $68.54M | $82.78M | $97.84M | $57.72M | $86.91M | $102.19M | $119.48M | $131.77M |
| Current liabilities | $15.77M | $14.27M | $13.97M | $12.03M | $9.99M | $10.73M | $13.15M | $9.06M | $9.07M | $9.61M | $12.67M | $10.11M |
| Total liabilities | $36.51M | $35.68M | $45.63M | $44.56M | $43.89M | $44.92M | $47.09M | $41.73M | $42.77M | $46.09M | $52.57M | $48.83M |
| Shareholders' equity | -$3.40M | $2.56M | $5.59M | $8.12M | $24.65M | $37.86M | $25.65M | $15.99M | $44.15M | $56.09M | $66.91M | $82.94M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.25M | -$7.48M | -$6.88M | -$9.45M | -$13.07M | -$14.05M | -$13.50M | -$7.87M | -$8.35M | -$11.68M | -$7.04M | -$15.38M |
| Capital expenditures | - | - | $0 | $0 | $196.0K | $0 | $11.0K | $0 | $0 | $15.0K | $4.0K | $1.86M |
| Free cash flow | - | - | -$6.88M | -$9.45M | -$13.27M | -$14.05M | -$13.52M | -$7.87M | -$8.35M | -$11.70M | -$7.04M | -$17.24M |
| Investing cash flow | $0 | $114.0K | $0 | $0 | -$184.0K | $0 | -$11.0K | $60.0K | $0 | -$15.0K | $101.0K | $21.14M |
| Financing cash flow | $9.68M | -$118.0K | $11.04M | $124.0K | $1.01M | -$414.0K | $51.29M | $2.44M | $0 | $0 | $556.0K | -$23.0K |
| Stock-based compensation | $1.05M | $1.31M | $1.43M | $1.55M | $1.53M | $1.20M | $605.0K | $668.0K | -$776.0K | $1.26M | $2.06M | $409.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | -100.0% | - | 390.2% | 69.4% | 13.6% | -100.0% | -80.9% |
| Operating margin | -85229.4% | -28850.0% | - | - | - | - | - | -918.2% | -841.6% | -1115.7% | - | -12981.1% |
| Net margin | -75000.0% | -26381.3% | - | - | - | - | - | -1742.1% | -705.9% | -829.0% | - | -4415.1% |
| Free cash flow margin | - | - | - | - | - | - | - | -474.7% | -525.8% | -800.6% | - | -5099.7% |
| Current ratio | 0.83 | 1.04 | 1.67 | 1.51 | 3.26 | 4.22 | 4.49 | 1.92 | 4.89 | 5.79 | 5.62 | 7.81 |
Source: XBRL data Senti Biosciences Holdings Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 13, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SNTI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SNTI | $22.0K | - | -$61.44M | -279263.6% | $6.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
SNTI FAQ
7 questionsWhat is SNTI revenue?
Senti Biosciences Holdings Inc. (SNTI) reported $22.0K of revenue for fiscal 2025 (ended Dec 31, 2025).Is SNTI profitable?
No. Senti Biosciences Holdings Inc. reported a net loss of $61.44M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SNTI have?
Senti Biosciences Holdings Inc. reported $6.46M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is SNTI free cash flow?
Senti Biosciences Holdings Inc. generated -$43.64M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$43.44M less capital expenditures.What is SNTI earnings per share?
Diluted earnings per share were -$2.73 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did SNTI last report financial results?
The latest statements here come from Senti Biosciences Holdings Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this SNTI financial data come from?
Quantisnow builds these statements from the structured XBRL data Senti Biosciences Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.